National Institute on Drug Abuse logo
NIDA SBIR/STTR

NIDA SBIR/STTR

Supports United States. small businesses advancing drug abuse intervention and treatment technologies.

OpenNational Institute on Drug AbuseUnited StatesDeep-tech · core fit

The National Institute on Drug Abuse (NIDA) channels more than $50 million per year to small U.S. businesses through the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs. Individual projects can receive up to $3.4 million in total funding across all phases. All awards are non-dilutive — grantees retain full equity in their companies. NIDA's SBIR/STTR portfolio focuses on pharmacotherapeutic products, medical devices, and other drug abuse research and treatment technologies, spanning areas such as addiction neuroscience, overdose prevention tools, diagnostics, and behavioral health platforms.

Eligibility under SBIR requires that the applicant be a U.S.-based for-profit small business with fewer than 500 employees, majority U.S.-owned, and independently operated. Nonprofit organizations, universities, and research institutions cannot receive SBIR awards as lead applicants, though they may serve as subcontractors. The STTR mechanism requires a formal research-institution partner with at least 30% of the work performed at that organization. Venture capital-backed companies can apply through NIH's special opt-in SBIR pathway. Award cycles are tied to NIH omnibus SBIR solicitations published on grants.gov, typically accepting applications on standard dates.

NIDA program staff strongly encourage pre-submission consultation and have published Target Product Profiles (TPPs) to help applicants align their technology with agency priorities before applying. Portfolio reviews and application guidance materials are available through the NIDA SBIR office. Phase I feasibility awards follow the standard NIH cap of approximately $300,000 over 6–12 months; Phase II development awards scale upward with the cumulative per-project ceiling of $3.4 million. Organizations at any early stage — from startup to established small business — can apply as long as they meet the employee and ownership criteria.

Pharmacotherapeutic products, medical devices, and drug abuse research and treatment innovations developed by US small businesses.

CycleiHow often this grant runs — e.g. annually, on a rolling basis, or a one-off call.Multiple per year
Next deadlineiThe next date applications are due. Rolling means you can apply any time.—
Decision timeiTypical time from the deadline to the funder's decision.—
Project durationiHow long the funded work is expected to run.—
Award typeiThe form of funding — grant, equity, loan, tax credit, etc.Grant
Match fundingiThe share of project costs you must cover yourself. 0% = fully funded.0%
Funding pooliThe total budget available across all awards in this round.$50M

Sign up free to see the funding breakdown

Sign up free to see the industries in scope

Sign up free to see the full eligibility

Sign up free to see the timeline

Last verified: 29 Jun 2026Source: nida.nih.gov